Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
bleeding time
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "bleeding time" in MCE Product Catalog:
2
Target:
Research Areas:
Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
2
2 Cited Publications
Synonyms: GS-9876 succinate
Target:
Research Areas:
Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
Target:
Research Areas:
JW480 is a selective KIAA1363/AADACL1 inhibitor with oral activity, featuring IC50 values of 12 nM against human KIAA1363, 20 nM against mouse KIAA1363. JW480 blocks lipid deacetylase activity to restrain HAG metabolism and lowers retinyl ester hydrolase function in hepatic stellate cells. JW480 reduces MAGE lipid levels and inhibits migration, invasion, survival and tumor growth of prostate cancer cells. JW480 lowers PKCδ phosphorylation, facilitates HAGP accumulation, diminishes platelet aggregation, dense granule secretion and Ca 2+ flux, delays arterial thrombosis and prolongs tail bleeding time in rats. JW480 can be used for the study of prostate cancer and thrombosis .
Cat. No.: HY-173268
CAS No.: 3051784-94-9
Target:
Research Areas:
UNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .
Cat. No.: HY-112998
CAS No.: 1270012-79-7
Synonyms: BIIB-031
Target:
Research Areas:
Cat. No.: HY-174829
CAS No.: 13198-99-7
Target:
Protease Activated Receptor (PAR) NF-κB Reactive Oxygen Species (ROS) Calcium Channel Akt ERK p38 MAPK PKC
Research Areas:
7,4'-Dimethoxy-3-hydroxyflavone is an orally active PAR4 antagonist. 7,4'-Dimethoxy-3-hydroxyflavone inhibits PAR4-mediated human platelet aggregation with an IC50 of 1.4 μM. 7,4'-Dimethoxy-3-hydroxyflavone inhibits PAR4-mediated human platelet aggregation and PAR4 signaling pathways, including NF-κB, Ca 2+/protein kinase C, Akt, ERK and p38. 7,4'-Dimethoxy-3-hydroxyflavone prevents vascular PAR4 expression, endothelial dysfunction and ameliorates oxidative stress in Streptozotocin (STZ) (HY-13753)-induced diabetic mice.
7,4'-Dimethoxy-3-hydroxyflavone prevents thrombosis in mice without affecting bleeding time [1][2].
Cat. No.: HY-120612
CAS No.: 1557206-59-3
Target:
Research Areas:
BMS-884775 is a selective and orally active P2Y1 antagonist with an IC50 of 0.1 nM for the human P2Y1 receptor. BMS-884775 has a similar efficacy in preventing arterial thrombosis to Clopidogrel (HY-15283) and Prasugrel (HY-15284), but treatment with BMS-884775 results in shorter bleeding time and lower bleeding risk. BMS-884775 can be used in research related to antiplatelet and arterial thrombosis-associated diseases .
Cat. No.: HY-117464
CAS No.: 1664361-37-8
Target:
Research Areas:
CM-352 (compound 5) is an inhibitor of matrix metalloproteinases (MMPs) (MMP-3: IC50=15 nM; MMP-10: IC50=12 nM). CM-352 has significant antifibrinolytic activity (EC50=0.7 nM) and can significantly prolong blood coagulation time. CM-352 can be used in anti-bleeding research .
Cat. No.: HY-P991169
CAS No.: 2955620-21-8
Synonyms: NXT007; RG6512; RO7589655
Research Areas:
Zemocimig (NXT007) is an activated factor VIII mimetic antibody. Zemocimig binds to FX, FIXa and their activated forms to form a ternary complex, bridges FIXa and FX on the phospholipid surface, and restores intrinsic prothrombinase activity. Zemocimig induces thrombin generation, acts as a procoagulant, antifibrinolytic agent and hemostatic agent, and can shorten aPTT, increase fibrin deposition, correct clotting time, and reduce bleeding parameters. Zemocimig is applicable to the research of hemophilia A .
Cat. No.: HY-19229
CAS No.: 176655-58-6
Target:
Research Areas:
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .
Cat. No.: HY-109091A
CAS No.: 1800046-97-2
Synonyms: GS-9876 monosuccinate
Target:
Research Areas:
Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
Cat. No.: HY-123400A
CAS No.: 133276-52-5
Synonyms: iso-DTTX30; iso-DT-TX 30 SE
Target:
Research Areas:
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
Cat. No.: HY-14854A
CAS No.: 1004551-83-0
Synonyms: ATI-5923 sodium
Target:
Research Areas:
Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
Cat. No.: HY-14854R
CAS No.: 867257-26-9
Synonyms: ATI-5923 (Standard)
Target:
Research Areas:
Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
Cat. No.: HY-14854S
Synonyms: ATI-5923-13C,d3
Cat. No.: HY-165360
CAS No.: 1225170-16-0
Target:
Research Areas:
JJ1 is a selective α-thrombin inhibitor with a Ki of 0.019 μM. JJ1 directly binds to the active site of α-thrombin to block its catalytic activity. JJ1 exhibits antithrombotic effects and prolongs activated partial thromboplastin time, prothrombin time, and tail bleeding time in mice. JJ1 can be used for the research of thrombotic diseases .
Cat. No.: HY-19517
CAS No.: 865451-66-7
Target:
Research Areas:
R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
Cat. No.: HY-P1711
CAS No.: 154447-41-3
Target:
Research Areas:
Cat. No.: HY-183409
CAS No.: 1941243-22-6
Synonyms: ONO-5450598
Target:
Research Areas:
ONO-7684 (ONO-5450598) is an orally active coagulation factor XIa (FXIa) inhibitor with a Ki value of 2 nM against human FXIa. ONO-7684 inhibits human FXIa in a competitive and reversible manner, reduces factor XI coagulation activity, prolongs activated partial thromboplastin time in a dose-dependent manner, and exerts no significant effects on PT/INR and the activity of related serine proteases. ONO-7684 exerts antithrombotic effects in vivo without prolonging bleeding time. ONO-7684 can be used in studies related to thromboembolic diseases .
Cat. No.: HY-109091R
CAS No.: 1800046-95-0
Synonyms: GS-9876 (Standard)
Target:
Research Areas:
Lanraplenib (Standard) is the analytical standard of Lanraplenib (HY-109091). This product is intended for research and analytical applications. Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
